Less than 10% of patients who could benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it issues its first recommendations on the medications.
Considering more than one billion individuals worldwide currently obese, it is urging broader and more equitable access to this class of drugs.
Per estimates, more than two billion could be obese by 2030 if no action is taken.
"Our new guidance recognises that obesity is a lifelong illness that can be addressed with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are key barriers to widespread access to the injections that can aid individuals in losing substantial body mass, notes the agency.
Skinny Jab Scarcity
Despite the present most optimistic case, the supply of such drugs would only suffice for around 100 million people – under 10% of those who need them, according to the health organization.
The advice calls on governments and firms to expand availability, through strategies such as voluntary licensing.
Exclusive production rights on a key compound – the primary ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs replicate a natural hormone to slow digestion, curb appetite and enhance satiety so users consume fewer calories.
Individuals usually start to lose weight within a few weeks of commencing the regular doses.
Studies suggests patients may see weight return a year later of discontinuing the medication, as their typical appetite return.
Being overweight or obese raises your chance for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity affects people in every country and was responsible for millions of deaths worldwide in 2024, per the WHO.
